Insider · CIK 0001709900
Antony C. Mattessich
Files at OCUL (OCULAR THERAPEUTIX, INC), AURA (Aura Biosciences, Inc.). First filing Feb 2, 2024, latest Feb 6, 2024.
In brief
Antony C. Mattessich files SEC Form 4 as director, CEO and president at OCUL (OCULAR THERAPEUTIX, INC), and also at AURA (Aura Biosciences, Inc.). Since Feb 2, 2024, Antony C. Mattessich has reported 0 open-market buys worth $0 and 2 open-market sells worth $186k, the latest filed on Feb 6, 2024.
A track record needs three past buys with six months of prices behind them; Antony C. Mattessich has 0, so none is measured yet.
The newest scored trade: sold $95k of OCUL on Feb 5, 2024, filed Feb 6, 2024, scored 50 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
OCUL: OCULAR THERAPEUTIX, INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | OCULAR THERAPEUTIX, INC | $95k 19,642 shares | -3% | +138% from low-35% from high | |
| 49Moderate | OCULAR THERAPEUTIX, INC | $91k 18,338 shares | -4% | +134% from low-36% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 30, 2024 | OCUL OCULAR THERAPEUTIX, INC. | 106,165 0.07% of outstanding | $619k | May 30, 2024 | $484k |
| May 29, 2024 | OCUL OCULAR THERAPEUTIX, INC. | 82,808 0.05% of outstanding | $484k | May 29, 2024 | none |
| Feb 5, 2024 | OCUL OCULAR THERAPEUTIX, INC. | 19,642 0.02% of outstanding | $95k | Feb 5, 2024 | $91k |
| Jan 31, 2024 | OCUL OCULAR THERAPEUTIX, INC. | 18,338 0.02% of outstanding | $91k | Jan 31, 2024 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 38,500 | Jun 15, 2026 |
| Jun 11, 2026 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 15, 2026 |
| Jun 17, 2025 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +13,000 | $0.00 | $0 | 23,500 | Jun 18, 2025 |
| Jun 17, 2025 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Jun 18, 2025 |
| Jun 20, 2024 | AURA Aura Biosciences, Inc. | AGrant or award Common Stock | +10,500 | $0.00 | $0 | 10,500 | Jun 24, 2024 |
| Jun 20, 2024 | AURA Aura Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,500 | $0.00 | $0 | 14,500 | Jun 24, 2024 |
| Feb 3, 2024 | OCUL OCULAR THERAPEUTIX, INC | AGrant or award Common Stock | +180,400 | $0.00 | $0 | 608,343 | Feb 6, 2024 |
| Feb 5, 2024 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock | +19,642 | $4.86 | $95k | 588,701 | Feb 6, 2024 |
| Feb 3, 2024 | OCUL OCULAR THERAPEUTIX, INC | AGrant or award Stock Option (Right to Buy)derivative | +549,400 | $0.00 | $0 | 549,400 | Feb 6, 2024 |
| Jan 31, 2024 | OCUL OCULAR THERAPEUTIX, INC | SOpen-market sale Common Stock | -18,338 | $4.95 | $91k | 427,943 | Feb 2, 2024 |
Questions about Antony C. Mattessich
Answered from the filings on this page, as of the latest one.
Is Antony C. Mattessich buying or selling?
Not in the last 12 months. Antony C. Mattessich's latest open-market trade on SEC Form 4 was sold $95k of OCUL on Feb 5, 2024.
How did Antony C. Mattessich's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Antony C. Mattessich has 0.
Where does Antony C. Mattessich file Form 4?
Antony C. Mattessich has filed Form 4 at OCUL (OCULAR THERAPEUTIX, INC) as President and CEO; AURA (Aura Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.